5 completed, 3 active not recruiting, 2 recruiting, 2 terminated. 7 Phase 3, 3 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Active not recruiting 3, Completed 3, Recruiting 1 |
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Not applicable | 1 | Terminated 1 |
Follow histrelin: new trials by email Literature Review of histrelin trials Research Report on histrelin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial Abiraterone, Apalutamide, Biospecimen Collection - Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer | Phase 2 | Recruiting | Mayo Clinic | 532 | 2024-06-03 | 2026-07-20 |
| Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial Bicalutamide, Buserelin, Darolutamide - Prostate Adenocarcinoma | Phase 3 | Active not recruiting | NRG Oncology | 2050 | 2021-12-06 | 2026-08-17 |
| Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease - Prostate Cancer, Oligometastasis | Phase 2 / Phase 3 | Active not recruiting | VA Office of Research and Development | 378 | 2021-07-01 | 2026-11-05 |
| Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial Apalutamide, Bicalutamide, Biospecimen Collection - Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8 | Phase 3 | Active not recruiting | NRG Oncology | 2753 | 2021-01-21 | 2026-08-17 |
| Skeletal Health and Bone Marrow Composition Among Youth GnRH Agonist - Gender Dysphoria in Children, Puberty | Not applicable | Terminated | Amy DiVasta, MD | 78 | 2020-09-15 | 2026-04-03 |
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer Abiraterone, Bicalutamide, Degarelix - Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 1273 | 2018-09-24 | 2026-10-08 |
| The Relation of GnRH Treatment to QTc Interval in Transgender Females Treatment with a GnRh agonists - Gender Dysphoria | Terminated | University of California, San Francisco | 3 | 2017-05-01 | 2018-12-26 | |
| Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer Enzalutamide, leuprolide acetate, goserelin acetate - Adenocarcinoma of the Prostate, Recurrent Prostate Cancer | Phase 2 | Completed | University of Colorado, Denver | 19 | 2015-11-11 | 2025-05-11 |
| Vantas Implant Retrieval Study Ultrasound or CT or MRI to locate implant - Prostate Cancer | Completed | Endo USA Inc., a Keenova Therapeutics Company | 12 | 2006-07-01 | 2024-01-02 | |
| Histrelin Subcutaneous Implant in Children With Central Precocious Puberty Histrelin Subcutaneous Implant - Central Precocious Puberty | Phase 3 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 36 | 2004-09-01 | 2021-01-08 |
| Study of Histrelin Subdermal Implant in Patients With Prostate Cancer Histrelin hydrogel implant, Zoladex goserelin implant - Prostate Cancer, Adenocarcinoma of the Prostate | Phase 3 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 59 | 2000-05-01 | 2024-01-02 |
| Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer histrelin acetate - Prostate Cancer, Adenocarcinoma of the Prostate | Phase 3 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 138 | 2000-04-01 | 2024-01-02 |
Prostatic Neoplasms (8) · Gender Dysphoria (1) · Neoplasm Metastasis (1) · Puberty, Precocious (1) · Salivary Gland Adenoma, Pleomorphic (1)
Endo USA Inc., a Keenova Therapeutics Company (4) · NRG Oncology (2) · Amy DiVasta, MD (1) · Mayo Clinic (1) · SWOG Cancer Research Network (1) · University of California, San Francisco (1) · University of Colorado, Denver (1) · VA Office of Research and Development (1)
United States (8) · Canada (2) · Chile (1) · Colombia (1) · Mexico (1) · Switzerland (1)
Abhishek Solanki, MD MS (1) · Brian Chapin (1) · Elizabeth Kessler, MD (1) · Erica A Eugster, MD (1) · Jacob J. Orme, MD, PhD (1) · Neil B Desai (1) · Paul L Nguyen (1) · Regulatory Division (1)
PMID 16515997, PMID 24295437, PMID 25803268, PMID 42117295
U10CA180868 (2), I01CX002277 (1), R01CA286127 (1), R01CA300454 (1), U10CA180888 (1)